Skip to main content

Health condition · Clinically reviewed

Pancreatic tumours, explained - from cancer to cysts to neuroendocrine disease.

Not one condition but several, with very different outlooks. This guide brings the whole spectrum together and points you to detailed pages on each type.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, NHS England and peer-reviewed pancreatic MDT sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance on adenocarcinoma, neuroendocrine tumours and cystic lesion surveillance.

Key facts

Pancreatic tumours at a glance.

The essentials, in plain English - what falls under this term, and why the pathway differs so much by type.

  • What it is

    An umbrella term for growths in the pancreas - ranging from aggressive adenocarcinoma to slow-growing neuroendocrine tumours and incidental cysts.

  • Main categories

    Pancreatic adenocarcinoma, pancreatic neuroendocrine tumours (PNETs) and cystic lesions with malignant potential.

  • Adenocarcinoma

    The most common type - often presents late with painless jaundice, weight loss and abdominal pain. Prognosis remains poor without early diagnosis.

  • Neuroendocrine tumours

    Rarer and behave very differently - some cause hormone-excess syndromes, others are found incidentally and grow slowly.

  • Cystic lesions

    Increasingly picked up incidentally on scans done for other reasons - most are benign but some carry malignant potential requiring surveillance.

  • Specialist MDT

    All pancreatic tumour types should be managed by a specialist hepatobiliary-pancreatic MDT given the complexity of diagnosis and treatment planning.

Why this guide matters

One organ, three very different diseases.

"Pancreatic tumour" covers a wide spectrum. The three points below shape everything else on this page.

  • Type changes everything

    Adenocarcinoma, neuroendocrine tumours and cysts behave, are staged and are treated very differently - getting the type right matters more than almost anything else.

  • Early detection is hard but valuable

    Adenocarcinoma often presents late, but neuroendocrine tumours and cysts are increasingly caught early on scans done for other reasons.

  • Specialist MDT care is essential

    Because of the complexity involved, every pancreatic tumour type benefits from assessment and treatment planning by a dedicated pancreatic MDT.

Types of pancreatic tumour

Three paths, three dedicated guides.

This page gives the overview - each type has its own in-depth guide covering diagnosis, staging and treatment in full.

  • Most common

    Pancreatic cancer

    Pancreatic adenocarcinoma is the most common form. It often presents late with painless jaundice, weight loss and abdominal pain, and prognosis remains challenging without early diagnosis.

    Read the full guide

  • Rarer, variable behaviour

    Pancreatic neuroendocrine tumours

    These arise from hormone-producing cells. Some cause hormone-excess syndromes with flushing or diarrhoea, others are entirely asymptomatic and found incidentally.

    Read the full guide

  • Often incidental

    Pancreatic cysts

    Cystic lesions with malignant potential are frequently found by chance on scans for other reasons. Most are watched with surveillance; some need resection.

    Read the full guide

How the diagnosis is made

From first suspicion to a clear plan.

The steps a UK specialist team will normally follow across all pancreatic tumour types, so you know what to expect and why.

  1. 01

    Assessing

    Symptom review and history

    Jaundice, unexplained weight loss, new-onset diabetes, abdominal or back pain, or an incidental finding on another scan.

  2. 02

    Assessing

    Blood tests

    Liver function tests, glucose, and tumour markers - CA19-9 for suspected adenocarcinoma, chromogranin A for suspected neuroendocrine disease.

  3. 03

    Assessing

    Cross-sectional imaging

    Contrast-enhanced CT or MRI to characterise the lesion, assess local spread and look for distant disease.

  4. 04

    Confirming

    Endoscopic ultrasound and biopsy

    EUS with fine-needle biopsy gives detailed local views and tissue diagnosis, distinguishing tumour type and grade.

  5. 05

    Confirming

    Functional and nuclear imaging

    For suspected neuroendocrine tumours, somatostatin-receptor imaging (such as Ga-68 DOTATATE PET) helps confirm the diagnosis and stage disease.

  6. 06

    Planning

    Specialist pancreatic MDT review

    Every case is discussed by a dedicated hepatobiliary-pancreatic multidisciplinary team before a treatment plan is agreed.

  7. 07

    Planning

    Staging and treatment planning

    Resectability, hormone activity and cyst risk features (size, growth, duct involvement) shape the final management pathway.

Typical timeline: a first suspicious finding to a specialist MDT plan, usually within a few weeks.

Symptoms

What pancreatic tumours can look like.

Presentation varies enormously by type - from late, dramatic symptoms to no symptoms at all. The features that mean it's time to seek urgent review.

  • Painless jaundice

    Yellowing of the skin and eyes without pain - a classic and important sign of adenocarcinoma in the head of the pancreas.

  • Unexplained weight loss

    Often accompanies adenocarcinoma and some neuroendocrine tumours - worth investigating promptly, especially in over-40s.

  • Abdominal or back pain

    Dull, persistent pain that can radiate to the back - a common but non-specific feature of larger tumours.

  • Hormone-excess symptoms

    Flushing, diarrhoea, low blood sugar or skin rashes can signal a functioning neuroendocrine tumour secreting hormones.

  • New-onset diabetes

    Sudden diabetes in later life, especially without the usual risk factors, can occasionally be an early clue to pancreatic cancer.

  • Incidental finding

    Many cystic lesions and some small neuroendocrine tumours are found by chance on a scan done for an unrelated reason.

  • Silent or asymptomatic disease

    Non-functioning neuroendocrine tumours and small cysts often cause no symptoms at all until they are larger or picked up incidentally.

  • Red flag - jaundice plus weight loss

    This combination warrants urgent same-pathway referral for pancreatic imaging - do not wait and watch.

Treatment

How pancreatic tumours are treated in the UK.

Management is type-specific - surgery and chemotherapy for adenocarcinoma, hormone-targeting and targeted therapy for neuroendocrine tumours, and surveillance or resection for cysts. Every plan is agreed by a specialist pancreatic MDT.

  • Surgical resection

    Whipple’s procedure (pancreaticoduodenectomy) or distal pancreatectomy for resectable adenocarcinoma or larger, higher-risk neuroendocrine tumours.

  • Chemotherapy

    Neoadjuvant, adjuvant or palliative chemotherapy for pancreatic adenocarcinoma, tailored to fitness and disease stage.

  • Somatostatin analogues

    Octreotide or lanreotide control hormone-excess symptoms and can slow growth in many neuroendocrine tumours.

  • Targeted and biological therapy

    Agents such as everolimus or sunitinib are used for selected advanced or progressive neuroendocrine tumours.

  • Peptide receptor radionuclide therapy

    A targeted radioactive treatment (PRRT) for somatostatin-receptor-positive neuroendocrine tumours that have progressed.

  • Cyst surveillance

    Regular MRI or EUS follow-up for low-risk cystic lesions, watching for size increase or worrying features over time.

  • Cyst resection

    Surgery for cysts with high-risk features - large size, main duct involvement, solid components or symptoms.

  • Palliative and supportive care

    Biliary stenting, pain management and nutritional support are central to care for advanced or unresectable disease.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your history and results and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Pancreatic cancer in adults: diagnosis and management (NG85).

  • NHS England. Neuroendocrine tumour service specification and referral pathways.

  • European Neuroendocrine Tumor Society (ENETS). Consensus guidelines for neuroendocrine neoplasms.

  • International Association of Pancreatology. Guidelines for management of intraductal papillary mucinous neoplasms and other pancreatic cystic lesions.

Red flags

When to seek urgent attention.

These situations, across any tumour type, warrant urgent same-pathway assessment rather than a routine wait.

  • Painless jaundice

    Yellowing of the skin or eyes without pain is a red flag for pancreatic adenocarcinoma and needs urgent imaging.

  • Rapid, unexplained weight loss

    Significant weight loss over weeks, especially with reduced appetite, deserves prompt investigation.

  • New diabetes in later life

    Diabetes appearing suddenly after the age of 50 without typical risk factors can occasionally point to an underlying pancreatic tumour.

  • Carcinoid crisis

    Severe flushing, low blood pressure and breathing difficulty in a patient with a known neuroendocrine tumour is a medical emergency.

  • Severe hypoglycaemia

    Recurrent, unexplained low blood sugar can signal an insulin-secreting neuroendocrine tumour (insulinoma) and needs urgent assessment.

  • Rapidly growing or symptomatic cyst

    Any cyst that grows quickly, develops solid components, or causes pain or jaundice needs urgent specialist reassessment.

  • Acute pancreatitis with a mass

    Pancreatitis occurring alongside an identified mass lesion should prompt urgent pancreatic MDT discussion.

  • Gastrointestinal bleeding

    Bleeding associated with a pancreatic tumour, or duodenal obstruction causing vomiting, needs same-day assessment.

  • Family history of pancreatic cancer

    A strong family history, or known genetic syndromes such as BRCA2 or Lynch syndrome, warrants a discussion about surveillance.

Living with it

Different diagnoses, a shared set of foundations.

Whatever the specific diagnosis, four things tend to help - supporting digestion, keeping to your surveillance schedule, reporting new symptoms early and using the wider support team.

A quiet reminder

You do not need to navigate this alone.

Specialist pancreatic teams see the full spectrum of these tumours regularly - ask questions, and ask again if something isn't clear.

  1. 01 Nutrition

    Support your digestion

    Pancreatic enzyme replacement and dietitian input help manage weight loss and malabsorption common across tumour types.

  2. 02 Monitoring

    Keep to your surveillance schedule

    Whether it is a cyst under watchful waiting or a treated neuroendocrine tumour, regular scans catch change early.

  3. 03 Symptoms

    Report hormone symptoms promptly

    Flushing, diarrhoea or unusual sweating episodes should be flagged to your team even between scheduled appointments.

  4. 04 Support

    Ask about the wider team

    Specialist nurses, dietitians and psychological support are usually available alongside your oncology or surgical team - ask what is offered.

Frequently asked

Everything we get asked about pancreatic tumours.

Quick answers on types, diagnosis, cyst risk and specialist MDT care.

  • What are pancreatic tumours?

    An umbrella term covering several different growths that arise in the pancreas. The three broad groups are pancreatic adenocarcinoma (the most common and most aggressive), pancreatic neuroendocrine tumours, and cystic lesions - each with very different behaviour, prognosis and treatment.

  • How is pancreatic adenocarcinoma different from a neuroendocrine tumour?

    Adenocarcinoma arises from the exocrine (digestive enzyme-producing) cells and tends to grow and spread quickly, often presenting late. Neuroendocrine tumours arise from hormone-producing cells and are usually slower-growing, though behaviour varies widely between individual tumours.

  • Are all pancreatic cysts cancerous?

    No - most pancreatic cysts found incidentally are benign. However, some types, particularly intraductal papillary mucinous neoplasms, carry a risk of progressing to cancer over time, which is why regular imaging surveillance is recommended for higher-risk cysts.

  • What tests confirm a pancreatic tumour?

    Diagnosis usually combines cross-sectional imaging (CT or MRI), endoscopic ultrasound with biopsy for tissue diagnosis, and blood tests such as CA19-9 for suspected adenocarcinoma or chromogranin A for suspected neuroendocrine tumours.

  • Why does every pancreatic tumour go to a specialist MDT?

    Pancreatic tumours are complex to diagnose and treat, and outcomes are strongly linked to specialist, high-volume care. A dedicated hepatobiliary-pancreatic multidisciplinary team brings together surgeons, oncologists, radiologists and specialist nurses to agree the best individual plan.

  • Can pancreatic neuroendocrine tumours be cured?

    Some can, particularly small, localised tumours removed surgically. Others are managed as a long-term condition with somatostatin analogues, targeted therapy or peptide receptor radionuclide therapy, with many people living for years with good symptom control.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.